[go: up one dir, main page]

WO2012073047A3 - Compositions and methods - Google Patents

Compositions and methods Download PDF

Info

Publication number
WO2012073047A3
WO2012073047A3 PCT/GB2011/052399 GB2011052399W WO2012073047A3 WO 2012073047 A3 WO2012073047 A3 WO 2012073047A3 GB 2011052399 W GB2011052399 W GB 2011052399W WO 2012073047 A3 WO2012073047 A3 WO 2012073047A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
bcl11afor
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/052399
Other languages
French (fr)
Other versions
WO2012073047A2 (en
Inventor
Pentao Liu
Walid Khaled
Shannon Burke
Song-Choon Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genome Research Ltd
Original Assignee
Genome Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1020468.3A external-priority patent/GB201020468D0/en
Priority claimed from GBGB1116340.9A external-priority patent/GB201116340D0/en
Application filed by Genome Research Ltd filed Critical Genome Research Ltd
Publication of WO2012073047A2 publication Critical patent/WO2012073047A2/en
Publication of WO2012073047A3 publication Critical patent/WO2012073047A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An inhibitor of BCL11Afor use in the prevention or treatment of cancer.
PCT/GB2011/052399 2010-12-03 2011-12-05 Compositions and methods Ceased WO2012073047A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1020468.3 2010-12-03
GBGB1020468.3A GB201020468D0 (en) 2010-12-03 2010-12-03 Bcl11a
GBGB1116340.9A GB201116340D0 (en) 2011-09-21 2011-09-21 Compositions and methods
GB1116340.9 2011-09-21

Publications (2)

Publication Number Publication Date
WO2012073047A2 WO2012073047A2 (en) 2012-06-07
WO2012073047A3 true WO2012073047A3 (en) 2012-09-13

Family

ID=45099139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/052399 Ceased WO2012073047A2 (en) 2010-12-03 2011-12-05 Compositions and methods

Country Status (1)

Country Link
WO (1) WO2012073047A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013308770B2 (en) 2012-08-29 2019-01-17 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
AU2013352156B2 (en) 2012-11-27 2018-12-06 Children's Medical Center Corporation Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
BR112015029327A2 (en) * 2013-05-24 2017-09-19 Roche Innovation Ct Copenhagen As B-CELL LYMPHOMA 11A OLIGONUCLEOTIDE/CLL (BCL11A) MODULATORS AND USES THEREOF
SG10201809290SA (en) 2014-04-25 2019-01-30 Childrens Medical Ct Corp Compositions and Methods to Treating Hemoglobinopathies
JP7288302B2 (en) 2015-05-08 2023-06-07 ザ チルドレンズ メディカル センター コーポレーション Methods of targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
EP3787600A4 (en) 2018-05-02 2022-02-16 The Children's Medical Center Corporation IMPROVED BCL11A MICRORNAS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GB201907999D0 (en) * 2019-06-05 2019-07-17 Cambridge Entpr Breast cancer detection methods
KR102672646B1 (en) * 2020-07-02 2024-06-07 연세대학교 산학협력단 A Method for Inhibiting Cancer Metastasis by Modulating Anchorage-Dependency of Cancer Cells
EP4285938A4 (en) * 2021-01-29 2024-12-25 Korea Advanced Institute of Science and Technology PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT BREAST CANCER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133923A2 (en) * 2005-06-16 2006-12-21 Bayer Healthcare Ag Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2010030963A2 (en) * 2008-09-15 2010-03-18 Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133923A2 (en) * 2005-06-16 2006-12-21 Bayer Healthcare Ag Diagnosis, prognosis and prediction of recurrence of breast cancer
WO2010030963A2 (en) * 2008-09-15 2010-03-18 Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ARGOS M ET AL: "Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 182, no. 2, 15 April 2008 (2008-04-15), pages 69 - 74, XP022606023, ISSN: 0165-4608, [retrieved on 20080411], DOI: 10.1016/J.CANCERGENCYTO.2008.01.001 *
B. YIN ET AL: "A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene", BLOOD, vol. 113, no. 5, 1 January 2008 (2008-01-01), pages 1075 - 1085, XP055017902, ISSN: 0006-4971, DOI: 10.1182/blood-2008-03-144436 *
DEREK M. DYKXHOORN ET AL: "miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases", PLOS ONE, vol. 4, no. 9, 1 January 2009 (2009-01-01), pages E7181, XP055017967, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0007181 *
DOUGHERTY C J ET AL: "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 370, no. 1, 23 May 2008 (2008-05-23), pages 109 - 112, XP022606115, ISSN: 0006-291X, [retrieved on 20080318], DOI: 10.1016/J.BBRC.2008.03.040 *
HUANG SHIXIA ET AL: "Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice", GENOME BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 6, no. 10, 30 September 2005 (2005-09-30), pages R84, XP021012944, ISSN: 1465-6906, DOI: 10.1186/GB-2005-6-10-R84 *
JANG JI-YOUNG ET AL: "Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 10, no. 1, 12 February 2008 (2008-02-12), pages R11, XP021041293, ISSN: 1465-5411 *
PENTAO LIU ET AL: "Bcl11a is essential for normal lymphoid development", NATURE IMMUNOLOGY, vol. 4, no. 6, 1 June 2003 (2003-06-01), pages 525 - 532, XP055017589, ISSN: 1529-2908, DOI: 10.1038/ni925 *
SATTERWHITE E ET AL: "The BCL11 gene family: Involvement of BCL11A in lymphoid malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 12, 1 December 2001 (2001-12-01), pages 3413 - 3420, XP002244631, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V98.12.3413 *
SONG CHOON LEE: "CHARACTERISATION OF BCL11 FUNCTIONS IN DEVELOPMENT USING GENETICALLY MODIFIED MICE", September 2008 (2008-09-01), Cambridge, UK, pages I-XX,264 - 278, XP002668289, Retrieved from the Internet <URL:ftp://ftp.sanger.ac.uk/pub4/theses/lee> [retrieved on 20120130] *
YOHEI SHIMONO ET AL: "Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells", CELL, vol. 138, no. 3, 1 August 2009 (2009-08-01), pages 592 - 603, XP055017610, ISSN: 0092-8674, DOI: 10.1016/j.cell.2009.07.011 *
ZHIYUAN ZHANG ET AL: "Notch3 in Human Breast Cancer Cell Lines Regulates Osteoblast-Cancer Cell Interactions and Osteolytic Bone Metastasis", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 177, no. 3, 1 September 2010 (2010-09-01), pages 1459 - 1469, XP055017782, ISSN: 0002-9440, DOI: 10.2353/ajpath.2010.090476 *

Also Published As

Publication number Publication date
WO2012073047A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
WO2012073047A3 (en) Compositions and methods
HK1213889A1 (en) Glutaminase inhibitors and method of use
EP2877159B8 (en) Efflux inhibitor compositions and methods of treatment using the same
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
EP2640442A4 (en) Vascular treatment devices and methods
IL206970A0 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
PT2340042E (en) Methods and compositions for the treatment of cancer
GB201020860D0 (en) Disulfiram formulation and uses thereof
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2012082494A3 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
WO2012061413A3 (en) Isoflavonoid compositions and methods for the treatment of cancer
WO2012018597A9 (en) Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2012024399A3 (en) Compositions comprising paulownin and/or paulownia extracts and uses thereof
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
WO2010120400A3 (en) Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
EP2552452B8 (en) EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
PL2862576T3 (en) Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis
AP2012006241A0 (en) Use of ferroquine in the treatment or prevention of malaria.
HK1189502A (en) Compositions and methods for the prevention and treatment of cancer
GB0808730D0 (en) Compositions and methods for the prevention and treatment of schistosomiasis
AU2008903693A0 (en) Compositions and methods for the prevention and treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791627

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791627

Country of ref document: EP

Kind code of ref document: A2